Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 19Neoplasms 12Colorectal Neoplasms 5Pain, Postoperative 4Fatigue 4Thyroid Neoplasms 3Stomatitis 3Pain 3Malnutrition 3Liver Neoplasms 3Depression 3Carcinoma, Hepatocellular 3Anxiety Disorders 3Stomach Neoplasms 2Sleep Initiation and Maintenance Disorders 2Polycystic Ovary Syndrome 2Parasomnias 2Motor Activity 2Lung Neoplasms 2Gastrointestinal Neoplasms 2Breast Cancer Female 2Agnosia 2Weight Loss 1Vomiting 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Urinary Incontinence 1Unilateral U/S PVB 1Ulcer 1

Interventions

Dexamethasone 5Magnetic Resonance Spectroscopy 4Cyclophosphamide 4Blood Specimen Collection 4Surveys and Questionnaires 3Prednisone 3Melphalan 3Lenalidomide 3Biopsy, Fine-Needle 3fluciclovine F-18 2carfilzomib 2Positron-Emission Tomography 2Mammography 2Injections 2Immunohistochemistry 2Gemcitabine 2Cytarabine 22-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 2weifuchun 1vistusertib 1venetoclax 1technetium 99m 1-(1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)-2-((1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)methyl)-9,14-dioxo-2,8,13,15-tetraazaoctadecane-7,12,16,18-tetracarboxylic acid) 1ricolinostat 1pomalidomide 1phosphoribosylformylglycinamidine synthetase 1pembrolizumab 1ofatumumab 1obinutuzumab 1lortalamine 1irinotecan sucrosofate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Disease × Control Groups × Clear all
NCT01844375 2019-11-04

A Trial of Preoperative CHO Drinks on Postoperative Walking Capacity in Colorectal Surgery

Siriraj Hospital

Phase NA Completed
70 enrolled 10 charts
Gastrointestinal

Disease, Colorectal Neoplasms, Mobility Limitation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡